These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The future of antihypertensive treatment. Israili ZH; Hernández-Hernández R; Valasco M Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579 [TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of beta1-adrenergic receptors in heart failure and hypertension. Mialet-Perez J; Liggett SB Arch Mal Coeur Vaiss; 2006 Jun; 99(6):616-20. PubMed ID: 16878723 [TBL] [Abstract][Full Text] [Related]
7. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. Schelleman H; Klungel OH; Witteman JC; Hofman A; van Duijn CM; de Boer A; Stricker BH Eur J Hum Genet; 2006 Jul; 14(7):860-6. PubMed ID: 16724011 [TBL] [Abstract][Full Text] [Related]
8. Evolution of pharmacogenomics. Somogy A Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics/genomics and personalized medicine. Sadée W; Dai Z Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R207-14. PubMed ID: 16244319 [TBL] [Abstract][Full Text] [Related]
10. Using genotyping to predict responses to anti-hypertensive treatment. Kurland L; Lind L; Melhus H Trends Pharmacol Sci; 2005 Sep; 26(9):443-7. PubMed ID: 16055200 [TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Arranz MJ; de Leon J Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics and the future of drug therapy. Hines RN; McCarver DG Pediatr Clin North Am; 2006 Aug; 53(4):591-619. PubMed ID: 16872995 [TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of osteoporosis: opportunities and challenges. Nguyen TV; Eisman JA J Musculoskelet Neuronal Interact; 2006; 6(1):62-72. PubMed ID: 16675890 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics considerations in the control of hypertension. Lupoli S; Salvi E; Barcella M; Barlassina C Pharmacogenomics; 2015 Nov; 16(17):1951-64. PubMed ID: 26555875 [TBL] [Abstract][Full Text] [Related]
17. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314 [TBL] [Abstract][Full Text] [Related]
18. Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Schelleman H; Stricker BH; Verschuren WM; de Boer A; Kroon AA; de Leeuw PW; Kromhout D; Klungel OH Pharmacogenomics J; 2006; 6(1):22-6. PubMed ID: 16314886 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of antihypertensive drugs: past, present and future. Johnson JA Pharmacogenomics; 2010 Apr; 11(4):487-91. PubMed ID: 20350127 [TBL] [Abstract][Full Text] [Related]